Valve Science Center at the Minneapolis Heart Institute Foundation and Abbott Northwestern Hospital, Minneapolis, MN, United States.
Department of Cardiovascular Surgery, University Hospital, Zurich, Switzerland.
Prog Cardiovasc Dis. 2017 Nov-Dec;60(3):405-414. doi: 10.1016/j.pcad.2017.11.003. Epub 2017 Nov 10.
Severe mitral regurgitation (MR) confers an adverse prognosis, frequently with debilitating symptoms of heart failure. While open surgical correction has been the standard of care for decades, novel catheter-based technologies have emerged that are highly effective in the treatment of MR. These percutaneous technologies, which include methods for both repair as well as valve replacement, have the potential to address unmet clinical needs in patients with MR, and serve as a viable alternative to surgery.
严重二尖瓣反流（MR）预后不良，常伴有心力衰竭的衰弱症状。虽然开放式手术矫正已成为数十年来的标准治疗方法，但新兴的经导管技术在治疗 MR 方面非常有效。这些经皮技术包括修复和瓣膜置换方法，有可能解决 MR 患者未满足的临床需求，并成为手术的可行替代方案。
